Novartis partners with Monte Rosa Therapeutics in a $5.7 billion deal to develop innovative treatments for immune-mediated ...

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector ...

Persistence: After one year, 50%–60% of SPP patients remained on therapy compared to 30%–40% in the retail channel—a ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy ...

The Aligos Therapeutics chairman, president, and CEO discusses his journey to building his own company and bringing an experienced team along with him.

The new administration has a different perspective of vaccines than the previous administration, causing confusion with the ...

Novo Nordisk urges employees back to the office while announcing 9,000 job cuts to streamline operations and enhance decision ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for ...

AbbVie’s stock surges 4.4% after securing 12 more years of exclusivity for Rinvoq, boosting sales projections and investor ...

The US market's significance in global pharma profits complicates straightforward price reductions.

Drugmaker aims to simplify operations, speed up decision-making, and reinvest savings into diabetes and obesity growth ...

Expectations for tight turnaround times, stringent quality control and compliance, and expedited responses to supply chain ...